2023/24 NIHR CRN High Level Objectives (HLOs)
This page presents the 2023/24 NIHR CRN High Level Objectives (based on version 1.1, approved by DHSC) and was updated on 31 July 2023.
Please note the number in parenthesis, e.g. (6), denotes the relationship between the measure in the 2023/24 High Level Objectives (i.e. this version) and the superseded version of High Level Objectives from previous years. Where there is more than one Measure per Objective, and the number of the Measure does not start with (1), this indicates that previous Measure(s) associated with the Objective have been removed.
A PDF version of the 2023/24 High Level Objectives (v1.1) is available on request to crncc.performance@nihr.ac.uk.
Study Delivery (SD)
Support sponsors to deliver their NIHR CRN Portfolio studies to recruitment target
Measure (6) = Percentage of open to recruitment commercial contract studies which are predicted to achieve their recruitment target
Ambition = 80%
Level = CRN
Note: The 2023/24 ambition value is an increase on the 2022/23 ambition value of 60%.
Measure (7) = Percentage of open to recruitment non-commercial studies which are predicted to achieve their recruitment target
Ambition = 80%
Level = CRN
Note: The 2023/24 ambition value is an increase on the 2022/23 ambition value of 60%.
Participant Experience (PE)
Demonstrate to participants in NIHR CRN supported research that their contribution is valued through collecting their feedback and using this to inform improvement in research delivery
Measure: Number of NIHR CRN Portfolio study participants responding to the Participant Research Experience Survey
Ambition = 18,000
Level = CRN
Note: The 2023/24 ambition value of 18,000 represents an increase of 4,000 on the 2022/23 ambition value.
Expanding our work with the life sciences industry to improve health and economic prosperity (LSE)
Sustain or grow commercial contract research
Measure: Number of new commercial contract studies entering the NIHR CRN Portfolio as a percentage of the total MHRA CT approvals for PHASE II-IV studies
Ambition = 75%
Level = CRN
Note: The 2023/24 ambition value of 75% is unchanged from the 2022/23 ambition value.
Version Control
Version number 1.1
Effective from date: 31 July 2023 (and also reflect in Q1 reporting)
Changes from v1.0:
Measures ESD (4) and (5) (relating to closed commercial and non-commercial studies respectively) have been removed
The 'Efficient Study Delivery' objective has been renamed as 'Study Delivery'
The Study Delivery objective (formerly the Efficient Study Delivery Objective) now reads 'Support sponsors to deliver their NIHR CRN Portfolio studies to recruitment target', to better reflect responsibilities for study performance.